Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Three new patents applied for to protect IP. This will build significantly more value.
HL going to $3 first stop.
And this was once 85c.
Fortuna CEO purchases company shares-
Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) reports that Jorge A. Ganoza, Chief Executive Officer of the Company, has increased his equity position in the Company by acquiring 170,000 common shares on the open market at an average price of US$2.59 per share.
This speaks volumes. The CEO recently bought an additional $440,300.00 of the companies shares. He knows how undervalued this is.
FSM is extremely undervalued.52wk high is $5.94.
It was $9.75 in mid 2016. Low share count of 159M. Big rebound coming.
Very interesting article. Thx.
They should use Stevia but I believe their label says sucralose. That's the one thing I don't like.
It's obvious nothing will happen quickly with the FDA.
“I’ve talked to beverage companies and they want to get into this space, but they are not interested in just throwing themselves headlong into an area without science and engagement with regulators,” said Coleen Klasmeier, a former FDA staff lawyer and now partner at law firm Sidley Austin.
“For years now, the agency’s position has been just to throw up their hands and say it’s a confusing issue,” said Daniel Fabricant, a former FDA official overseeing dietary supplements, who is now chief executive of the Natural Products Association representing the supplement industry.
In addition to Friday’s hearing, the FDA has set a deadline of July 2 for written comments on the issue. It also convened a working group led by Deputy Commissioner Amy Abernethy to explore ways CBD products might be sold legally, the impact of such products on public health, and whether new FDA rules or congressional legislation may be needed.
In a string of tweets on Friday, Abernerthy summed up main points she and FDA officials were hearing over and over at the meeting: “Key questions about product safety need to be addressed. Data are needed to determine safety thresholds for CBD...There are both positive supporters of cannabis-cannabis derived products including CBD and also concerned citizens worried that widely available products can be harmful.”
That hasn’t stopped restaurants like burger chain Carl’s Jr. from selling CBD-infused food, as there has been little enforcement.
“From the CBD companies’ perspective, if they don’t keep pushing forward they’re going to miss their window of opportunity to gain market control,” said Robert DiPisa, co-chair of the cannabis law group at New Jersey-based firm Cole Schotz.
I'm very positive on KGKG. Just saying.
LexaGene webinar, June 6th, 8am PST. Everyone welcome.
https://event.webcasts.com/starthere.jsp?ei=1245926&tp_key=4a31cc5ce9
Totally agree. These companies must stay away from bad sweeteners like sucralose. Go with organic non-GMO pure stevia instead. That's a natural plant. 0 sugar, 0 calories, 0 carbs, great taste. Much healthier.
I like em both, A LOT.
Think you're right about the FDA. Doubt they will approve anything anytime soon. They're like the AMA. Takes forever.
Calif may be the 8th largest economy but they're all on welfare and foodstamps.
New Investor Presentation. Very positive.
http://lexagene.com/wp-content/uploads/2019/05/LXG_Company-Presentation_15May2019.pdf
I'm talking about the FDA approving CBD in food and drinks not hemp. They have not.
The FDA knows the farm bill passed. But did they follow? No. They are arrogant and may not roll over soon. Just like the Fed has not on mj or mj bank accounts.
Never trust the govt to do the right thing.
Thanks. Good summary. We know FDA approval is expensive. Do you know what it will cost?
Yes, vol more than KG. Go VATE.
A NJ sells 200shs @ 4c = $8.00. Manipulator.
$4.00 in a few years would be awesome. I could take 100 times my investment.
Snapped up 33k at 0.036.
LexaGene Completes Development of Antibiotic Resistance Panel
Another huge announcement from LexaGene.
https://finance.yahoo.com/news/lexagene-completes-development-antibiotic-resistance-115800601.html
LexaGene presents to the USDA on June 19.
LexaGene’s CEO Invited by USDA to Present a Seminar on the Benefits of Adopting Rapid Genetic Testing to Improve Food Safety
There will be many USDA agencies there watching LexaGene present their amazing technology that can improve food safety. Only one of the many vast applications their LX machines addresses. Every food supplier will want to own their genetic analyzer devices that can detect pathogens in an hour. Allowing them to potentially save millions of dollars and possibly lives as well.
LexaGene has staggering potential. I'm buying more too. As they have stated the applications are VAST.
LexaGene’s Technology Identifies Genetic Mutations Directly from Cheek Swabs. Another huge market. $6Billion
LexaGene has demonstrated the ability for the same technology to be used for personal genotyping, which has a market value of greater than $6 B. The applications for genotyping (i.e. understanding genetic sequences in areas of scientific/clinical importance) are vast, including research focused on cancer and neurological diseases, as well as pharmacogenomic testing to determine a person’s genetic response to medication.
https://finance.yahoo.com/news/lexagene-technology-identifies-genetic-mutations-115500510.html
Provides safety for cannabis users. That is HUGE!!
LexaGene’s Technology Successfully Detects a Common Fungus That Damages Agricultural Crops including Cannabis.
GlobeNewswire•April 30, 2019
Robust testing capabilities address needs of the $24.6B food safety testing* and $6.29B agricultural testing markets**
BEVERLY, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that its LX analyzer successfully detects Botrytis cinerea, also known as Gray Mold, which is a common agricultural pathogen responsible for $10 to $100 billion in agricultural losses worldwide each year.*** This fungus infects over 200 plant species causing the most yield loss in strawberries, grapes and cannabis.
For this study, LexaGene’s scientists used the LX analyzer technology to process vegetable washes from strawberries that were suspected of premature decay due to a plant pathogen as well as wash from strawberries that appeared healthy. The LX analyzer generated very clear and conclusive results for the detection of Botrytis in the prematurely decaying strawberries but none in the healthy strawberries.
Dr. James Marsden, former advisor to the White House, Director of Food Safety at Chipotle Mexican Grills, and member of the Company’s Scientific Advisory Board states, “One of LexaGene’s value propositions is that its technology will give food producers the ability to screen their crops for pathogens that may wipe out the entire farm, as well as screen the finished food products for human pathogens that could lead to expensive recalls and irreparable brand damage. This innovative LX technology will have a big impact on the industry by providing a complete testing solution to food producers, rather than addressing just half of their concerns.”
A key element to having extremely sensitive PCR-based technology is to be able to access the genetic material inside pathogens, many of which have very strong cell walls, particularly fungi. These strong cell walls need to be broken down in order to get to the DNA inside. Proving that the LX analyzer can easily detect fungal DNA is a testament to the robustness of its DNA extraction chemistry.
Dr. Jack Regan, LexaGene’s CEO and Founder comments, “In conversations with prospective customers, some have asked whether LexaGene’s technology can detect both human and plant pathogens, to which the answer is ‘yes’. Previously, we reported successful detection of human foodborne pathogens such as E. coli and Staphylococcus, and here we are reporting that the LX analyzer can also detect plant pathogens. Data from this fungal study further indicate that the LX technology will offer best-in-class sensitivity for detecting rare pathogens. Exceptional sensitivity is important, as early detection will allow farmers to potentially avoid millions of dollars in crop losses due to Botrytis and other plant pathogens."
https://finance.yahoo.com/news/lexagene-technology-successfully-detects-common-070000204.html
They plan to have the LX commercialized and ready for sale by Q1 2020.
This is break through technology that will revolutionize many industries. I have faith in the brilliant management team. Holding heavy and waiting for an inevitable buy out.
This is Nick Hodge's latest comment on Lexagene.
LexaGene (TSX-V: LXG)(OTC: LXXGF), fresh off a C$2.8 million raise, has announced that Dr. Jame Marsden has joined its advisory board to steer its penetration of the food industry. Marsden just retired from Chipotle, where he led a multi-year effort to rebuild the company’s reputation after multiple food illness episodes. He has served as an adviser to the White House on food safety and nutrition issues. Marsden says, "The food industry has been looking for the right genomics-based technology to adopt to help make their products safer. Lexagene's technology has the speed, breadth of detection, sensitivity and ease of use that the industry is demanding, and it is affordable enough for widespread adoption. Lexagene has an opportunity to set the standard for genomics-based pathogen detection in the food industry, and I look forward to helping them achieve this goal." The food angle is on top of the veterinary angle that I’ve been covering the past few months. LexaGene is a buy as it trades at C$0.67, and is due for a run toward $1.00.
LexaGene is pleased to announce that food safety innovator Dr. James Marsden has joined LexaGene’s Scientific Advisory Board (SAB) to steer LexaGene’s penetration into the food industry.
LexaGene’s LX Technology Successfully Detects Pathogenic E. coli O157:H7 Bacteria from Romaine Lettuce Wash
A Significant Step Toward Addressing a $25B Market Opportunity
BEVERLY, Mass. – Mar 5, 2019 – LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that their LX technology successfully detected E. coli O157:H7 in a blinded study focused on romaine lettuce wash.
In the United States, the O157:H7 strain of E. coli causes an average of 73,000 illnesses annually1 with an annual cost of illness of $405M.2 In 2018, two separate outbreaks of E. coli O157:H7 contaminated romaine lettuce occurred, causing an estimated 272 illnesses and 5 deaths.3 Historically, fresh and freshcut produce cause more foodborne illnesses than any other food commodity since many of the fresh produce products are not routinely treated with chemicals to kill microbes.4
Dr. Jack Regan, LexaGene’s CEO and Founder, adds, “Our genetics-based technology is extremely sensitive and will return results in ~ 1 hour. The LX product line will minimize the time perishable food items spend in storage facilities and will help food companies avoid costly recalls and brand damage like we saw from the romaine lettuce recalls during 2018.”
Mr. Shawn Stevens, founding member of Food Industry Counsel LLC, the only law firm in the U.S. that exclusively represents food industry clients, states, “Food producers are increasingly paralyzed with fear over E. coli and other common food-borne pathogens. The average Class I recall costs ~ $30M, and some recalls are even more expensive.5 To add insult to injury, food producers, restaurants, and retailers are getting hit with lawsuits over these outbreaks. The food industry is continuing to look for ways to better protect itself. The industry has long relied on culture-based testing and the overwhelming sentiment is that genomic-based testing could greatly improve the ability and speed to detect potentially contaminated food items. This is why many forward-thinking food companies have expressed interest in working with LexaGene to evaluate their technology.”
Daryl Rebeck, LexaGene’s President, comments, “We just announced a very successful veterinary clinical study where the LX technology was found to be 97.5% concordant with reference laboratory generated results. Here, we are demonstrating the value of our LX technology not only for the veterinary markets but also expanding our scope to address the dire technological needs in the food safety industry, which is estimated to be a $24.6B market opportunity by 2023.6 This is a great example of the versatility of LexaGene’s technology.”
Dr. Regan concludes, “In the food industry, there is a strong demand for technology that can screen samples for multiple pathogens at once – and return results in as little time as possible. Many of the current testing methods generally take up 2 days for results. Our technology has the potential to provide food safety officers with sufficient information in just one hour allowing them to ship their perishable food items faster. As we move forward, we will continue expanding our screening capabilities in order to offer the food industry the most robust and comprehensive sample-to-answer solution possible.”
June 19th presentation for Govt agencies.
When will they do their reverse split?
Getting in front of all these Govt agencies on June 19 is huge.
LexaGene’s CEO Invited by USDA to Present a Seminar on the Benefits of Adopting Rapid Genetic Testing to Improve Food Safety
BEVERLY, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that Dr. Jack Regan, LexaGene’s CEO and Founder, was invited by the Food Safety and Inspection Service (FSIS), an agency of the United States Department of Agriculture (USDA), to present a seminar on the benefits of using LexaGene’s LX technology to help detect contaminated food items and prevent recalls.
Invited guests of this seminar include individuals representing multiple federal agencies such as the Food and Drug Administration (FDA), the Animal and Plant Health Inspection Service (APHIS), the Centers for Disease Control and Prevention (CDC), the Environmental Protection Agency (EPA), the National Institute of Food and Agriculture (NIFA), the Food & Nutrition Service (FNS), the Agricultural Research Service (ARS), and the Agricultural Marketing Service (AMS).
Dr. Regan’s presentation on using rapid genetic analysis for automated pathogen testing in the food industry will be given as part of the FSIS Science and Technology Seminar Series on June 19, 2019, from 1-2 pm EDT at Patriots Plaza III in Washington, DC. The FSIS Seminar Series fosters information exchange between FSIS personnel and professionals in public health, food science and technology, microbiology, risk assessment, infectious disease, veterinary medicine and other related sciences.
Dr. Jack Regan, LexaGene’s CEO and Founder, states, “I’m honored to be selected by the USDA to present on this topic. I look forward to sharing my knowledge and passion on the advantages of using LexaGene’s technology to dramatically improve food safety.”
Would someone layout all the debt SHMP has coming due please. Thx.